Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...

Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. Galectin Therapeutics ( NASDAQ:GALT – Get Free Report ) last posted its earnings results on Monday, March 31st.

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE raised its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT – Free Report ...

NORCROSS, Ga., April 15, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal ...

NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results ...